Online Program Home
My Program

Abstract Details

Activity Number: 117
Type: Topic Contributed
Date/Time: Monday, August 1, 2016 : 8:30 AM to 10:20 AM
Sponsor: Biopharmaceutical Section
Abstract #319856
Title: Adjustment for Multiplicity in Clinical Trials: When Is It Necessary and When Is It Not?
Author(s): Boguang Zhen*
Companies: FDA
Keywords: Adjustment ; Multiplicity ; Clinical Trials
Abstract:

It is inevitable to face a multiplicity issue in many clinical trials. While this issue is less important for earlier phase exploratory clinical studies, it is critical for adequate and well-controlled clinical trials due to the confirmatory nature of the trials and the fact that regulatory decision is made primarily based on the evidence from them. Sources of multiplicity include, but are not limited to: multiple endpoints, multiple doses, multiple looks, multiple time-points, multiple analysis methods, multiple subgroups, etc. It is not always clear when it is necessary to adjust for multiplicity and when it is not. This talk will first introduce the multiplicity issue and concerns on it, and then focus on the consideration on whether there is a need for adjustment from a regulatory perspective. Hypothetical examples are used to assist the discussions.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2016 program

 
 
Copyright © American Statistical Association